Effects of metabolic syndrome on prostate specific antigen level, prostate volume and international prostate symptom scores in patients with benign prostatic hyperplasia
Background and objective: Benign prostatic hyperplasia involves the enlargement of prostatic glandular tissue and narrowing of the urethra. It affects bladder storage or emptying. Most of the men with benign prostatic hyperplasia have no symptoms. This study aimed to compare international prostate symptom scores, prostate specific antigen level and prostate volume in patients having benign prostatic hyperplasia with and without metabolic syndrome.
Methods: This study involved 85 patients with benign prostatic hyperplasia who were divided into two groups. The first group included 40 participants who were only suffering from benign prostatic hyperplasia and the second group involved 45 participants who were suffering from both metabolic syndrome and benign prostatic hyperplasia. The division of subjects was performed depending on three abnormal parameters out of five parameters, such as body mass index (BMI >25kg/m2), dyslipidemia (Triglyceride ≥150 mg/dl, High density lipoprotein-C <40 mg/dl), blood pressure (BP ≥130/85 mmHg), fasting plasma glucose (PG ≥110 mg/dl).
Results: Patients with metabolic syndrome at diagnosis appears to have significantly higher levels of prostate specific antigen comparing with patients without metabolic syndrome, 3.9±0.26 and 2.7±0.21, respectively. Similarly, patients with metabolic syndrome at diagnosis had significantly higher prostate volume levels (72.69 ± 2.69 ml) comparing to patients without metabolic syndrome (46 ± 2.44 ml). Patients with metabolic syndrome at diagnosis showed considerable higher international prostate symptom scores level (23.62 ± 0.62) compared to patients without metabolic syndrome (18.87 ± 0.327).
Conclusions: benign prostatic hyperplasia patients having metabolic syndrome have significantly higher values of prostate specific antigen levels, prostate volume and international prostate symptom scores compared to benign prostate hyperplasia patients without metabolic syndrome.
Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; (49(4):651-8.
Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010; 16;375(9710):181-3.
Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005; 29:310-6.
He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 2016; 19(1):7-13.
Roehrborn CG, Nuckolls JG, Wei JT, Steers W, BPH Registry and Patient Survey Steering Committee. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU International 2007; 100(4):813-9.
Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benignprostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007; 177:1395-400.
Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW. Effects of obesity on lower urinary tract symptoms in Korean BPH patients. Asian J Androl 2009; 11:663-8.
Freedland SJ, Platz EA, Presti JC, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum PSA and prostate size: implications for prostate cancer detection. J Urol 2006; 175:500-4.
Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298:2275- 80.
Sohn JC, Lim MS, Chang HS, Park CH, Kim CI. The association of body mass index and prostate-specific antigen. Korean J Urol 2007; 48:1121-4.
Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 2005; 66:819-23.
Kim YD, Yang WJ, Song YS, Park YH. Correlation between prostate volume and metabolic or anthropometric factors in male visitors to a health promotion center. Korean J Urol 2008; 49:139-44.
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168:599-604.
Liu M, Eang JY, Zhu L, Wan G. Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men younger than 50 years of age. Asian J Androl 2011; 13(4):640-3.
Loeb S, Carter HB, Schaeffer ME, Ferrucci L, Kettermann A, Metter EJ. Should prostate-specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 2009; 182(6):2646-51.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).